



Department
of Health &
Social Care

The 2019 Voluntary Scheme for Branded Medicines Pricing and Access and The Branded Health Service Medicines (Costs) Regulations 2018

**Aggregate net sales and payment
information 22 May 2019**

Published July 2019

Aggregate Net Sales and Payment Information — 20 May 2019

TABLE 1 — Unaudited Sales Reports: Measured Sales

Aggregate Net Sales Subject to Affordability Mechanism (Measured Sales)

Year	2019 Voluntary Scheme	Statutory Scheme	Parallel Imports	Total
2018 Q1	£2,154M	£ 391M	£140M	£ 2,685M
2018 Q2	£2,194M	£ 412M	£147M	£ 2,753M
2018 Q3	£2,244M	£ 420M	£151M	£ 2,814M
2018 Q4	£2,293M	£ 422M	£158M	£ 2,873M
2018 Total	£8,884M	£1,646M	£595M	£11,125M
2019 Q1	£2,187M	£ 410M	£145M	£ 2,742M

Table 1 notes

1. Table 1 sets out aggregate information to date for calendar years 2018 and 2019. It includes unaudited financial information reported by 2019 Voluntary Scheme Members, companies regulated by the statutory scheme and information received on parallel imports.
2. The baseline for Measured Sales in respect of the statutory scheme and parallel imports has been calculated in accordance with Annex 4, paragraph 1 of the 2019 Voluntary Scheme.
3. The information set out is the Aggregate Net Sales subject to the Affordability Mechanism (Measured Sales), which will be used to assess the growth of the branded medicines bill.
4. Measured Sales is defined in the glossary of the 2019 Voluntary Scheme for Branded Medicines Pricing and Access as "Sales of Scheme Products by Scheme Members, Statutory Scheme Sales and Parallel Import Sales, but excluding exemptions from Measured Sales".

TABLE 2 — 2019 Voluntary Scheme Sales Reports: Eligible Sales and resulting Total Scheme Payments

Period	Aggregate Eligible Sales (Column 1)	Resulting aggregate Scheme Payments (Column 2)
2019 Q1	£2,056M	£197M

Table 2 notes

1. Table 2, which is derived from unaudited quarterly Sales Reports provided by members of the 2019 Voluntary Scheme, sets out aggregate annual audited and unaudited quarterly information showing Eligible Sales covered by the Scheme Payment and the resulting Scheme Payments.

There are two columns of information:

Column 1 — Aggregate Eligible Sales;

Column 2 — Resulting aggregate Scheme Payments due for the respective periods.

Note: Eligible Sales is defined in the Glossary of the 2019 Voluntary Scheme as "Sales of Scheme Products but excluding Exemptions from Eligible Sales". The percentage payment applies to these sales, which exclude New Active Substance (NAS) Sales. NAS Sales are included in the calculation of the overall sum to be repaid across all Scheme Members. However, sales of products with a NAS designation which were made within 36 months from the date that the Marketing Authorisation (MA) was granted (if the MA was granted on or after 1 January 2018) are excluded from the sales used to calculate the payment by each company.

TABLE 3 — Statutory scheme Sales Reports: net sales covered by the statutory scheme payment and resulting payments

Statutory Scheme payment and resulting payments	Jan-Mar 2019
Aggregate net sales covered by the applicable annual statutory scheme payment (a)	£139M
Resulting aggregate statutory scheme payment (b)	£14M
Net sales of extant frameworks and public contracts subject to 7.8% payment (c)	£52M

Resulting statutory scheme 7.8% payment (d)	£4M
Total resulting statutory scheme payment (b + d)	£18M

Table 3 notes

1. Table 3 is derived from unaudited statutory scheme Sales Reports. It sets out aggregate unaudited quarterly information showing net sales covered by the statutory scheme payment and the resulting payments.

General notes

Note 1: The information in all tables is that held on the Department of Health and Social Care's database at 22 May 2019.

Note 2: Totals may not sum due to rounding.

Note 3: All tables are subject to future correction where errors are discovered or where audited data replaces best available data and will be updated at each quarterly publication point to reflect the latest available information. The audit and reconciliation arrangements are set out in paragraphs 4.26-4.31 of the 2019 Voluntary Scheme. The statutory scheme audit requirements are set out at paragraph 23 of the Regulations.

© Crown copyright 2019

Published to GOV.UK in pdf format only.

Community Care/Medicines and Pharmacy/Medicines Pricing and Supply

www.gov.uk/dhsc

This publication is licensed under the terms of the Open Government Licence v3.0 except where otherwise stated. To view this licence, visit nationalarchives.gov.uk/doc/open-government-licence/version/3

Where we have identified any third-party copyright information you will need to obtain permission from the copyright holders concerned.

